FDA

Pharmalot Ed Silverman

STAT Plus: Florida’s gambit to import drugs from Canada: ‘a complicated road’ ahead

Exclusive Casey Ross

STAT Plus: Backed by Mayo Clinic and Microsoft, a nonprofit forms to test AI tools used in health care

The Readout Meghana Keshavan

STAT Plus: Why did Allogene cancel two clinical trials for its off-the-shelf cell therapy?

Pharmalot Ed Silverman

STAT Plus: FDA is blasted by advocates for pursuing a deal with data provider that has ties to opioid makers

The Pharmalot View Ed Silverman

STAT Plus: Consumer health advocate Sid Wolfe was a thorn in the side. We’re all the better as a result

Health tech Casey Ross and Katie Palmer

STAT Plus: 2024 could be a turning point for the regulation of AI in health care

First Opinion Eleanor Garrow-Holding

There’s a less intimidating alternative to EpiPens for dangerous allergic reactions. Why won’t the FDA approve it?

Politics John Wilkerson

STAT Plus: 3 FDA staffers to watch in 2024

Letters to the editor Torie Bosch

STAT readers on patient advocacy, the utility of diagnostic tests, and more

Health Angus Chen

STAT Plus: FDA alters warning label for Carvykti CAR-T, although link to secondary cancers is unclear

The Readout Damian Garde

STAT Plus: The clock is ticking, and Cytokinetics is running out of December

Biotech Damian Garde

STAT Plus: FDA approves AstraZeneca, Ionis treatment for rare nerve disease

Morning Rounds Elizabeth Cooney

Morning Rounds: Why health care costs are nearly a fifth of the GDP

The Readout Damian Garde

STAT Plus: BioMarin appeases an activist

A STAT Investigation Nicholas Florko

STAT Plus: Medical marijuana companies are using pharma’s sales tactics with little of the same scrutiny

Pharma John Wilkerson

STAT Plus: Drugs are still mostly tested in white men. Will the FDA change that next year?

The Readout Meghana Keshavan

Inhaled vaccines could stop Covid infections, monkey studies show

The Readout Meghana Keshavan

STAT Plus: The legal pathway for experimental, ultra-rare disease treatments is rocky and expensive

The Readout Meghana Keshavan

STAT Plus: FDA chastens pet companies over antibiotics

Pharmalot Ed Silverman

STAT Plus: In response to criticism, FDA publishes new database of wayward clinical trial sponsors

Pharma Annalisa Merelli

STAT Plus: Why FDA product recalls have spiked in recent years

First Opinion Eva Temkin and Grace Colón

In mifepristone case, the Supreme Court must affirm the FDA’s authority. Medical innovation is at risk

Politics Sarah Owermohle

STAT Plus: Supreme Court will decide abortion pill access

The Readout Meghana Keshavan

STAT Plus: The biotech news you missed from the weekend

Biotech Angus Chen

STAT Plus: Was CAR-T therapy a bystander or driver of lymphoma? Researchers examine first published case

Biotech Brittany Trang

STAT Plus: Tough road ahead for Bluebird Bio despite FDA approval for sickle cell therapy

The Readout Meghana Keshavan

CRISPR is about to make history. Here’s the 5-minute rundown of what to expect

Health Associated Press

White House delays menthol cigarette ban, alarming anti-smoking advocates

Morning Rounds Elizabeth Cooney

STAT Plus: Morning Rounds: Couples share high blood pressure, and other health stories you should read today